Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.72 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | STAT1 | P42224 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885125 | 0.89 | DYRK1A (0.68) | DYRK1ARAB9ASMN1; SMN2NPC1STAT1 | |
| SCHEMBL13486514 | 0.87 | RAB9A (0.66) | DYRK1ARAB9ASMN1; SMN2NPC1STAT1 | |
| SCHEMBL16896939 | 0.87 | RAB9A (0.67) | DYRK1ARAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL240597 | 0.86 | SMN1; SMN2 (0.72) | DYRK1ARAB9ASMN1; SMN2NPC1STAT1 | |
| SCHEMBL13486431 | 0.85 | DYRK1A (0.67) | DYRK1ARAB9ASMN1; SMN2NPC1STAT1 | |
| SCHEMBL13766404 | 0.85 | RAB9A (0.63) | DYRK1ARAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL7734175 | 0.85 | DYRK1A (0.67) | DYRK1ARAB9ASMN1; SMN2NPC1STAT1 | |
| SCHEMBL13766447 | 0.84 | RAB9A (0.68) | DYRK1ARAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL2175580 | 0.84 | DYRK1A (1.00) | DYRK1ARAB9ASMN1; SMN2NPC1CYP1A2 | |
| SCHEMBL6218888 | 0.82 | DYRK1A (0.60) | DYRK1ARAB9ASMN1; SMN2NPC1STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | DYRK1A 2694/4885RAB9A 1042/4885SMN1; SMN2 3325/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | DYRK1A 1201/4885RAB9A 1166/4885SMN1; SMN2 2183/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | DYRK1A 1783/4885RAB9A 741/4885SMN1; SMN2 1464/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | DYRK1A 673/4885RAB9A 2801/4885SMN1; SMN2 4472/4885 |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | DYRK1A 1215/4885RAB9A 2857/4885SMN1; SMN2 2350/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | DYRK1A 2694/4885RAB9A 1042/4885SMN1; SMN2 3325/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | DYRK1A 2987/4885RAB9A 1186/4885SMN1; SMN2 2859/4885 |
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3C3, PRKACA | DYRK1A 1170/4885RAB9A 890/4885SMN1; SMN2 1812/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | DYRK1A 1502/4885RAB9A 867/4885SMN1; SMN2 1064/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | DYRK1A 2224/4885RAB9A 984/4885SMN1; SMN2 3072/4885 |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | DYRK1A 1215/4885RAB9A 2857/4885SMN1; SMN2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.